CoChat

User’s guide to mechanism of action and clinical use of GLP-1 receptor agonists

Shaefer, Charles F, Kushner, Pamela, Aguilar, Richard · 2015 · Postgraduate Medicine

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are injectable glucose-lowering medications approved for the treatment of adult patients with type 2 diabetes mellitus (T2DM). This article provides practical information to guide primary care physicians on the use of GLP-1RAs in patients with T2DM. Two short-acting (once- or twice-daily administration; exenatide and liraglutide) and three long-acting (weekly administration; albiglutide, dulaglutide and exenatide) GLP-1RAs are currently approved in the US. These drugs provide levels of GLP-1 receptor agonism many times that of endogenous GLP-1. The GLP-1RAs have been shown to significantly improve glycemic parameters and reduce body weight. These agents work by activating GLP-1 receptors in the pancreas, which leads to enhanced insulin release and reduced glucagon release-responses that are both glucose-dependent-with a consequent low risk for hypoglycemia. Effects on GLP-1 receptors in the CNS and the gastrointestinal tract cause reduced appetite and delayed glucose absorption due to slower gastric emptying. The most common adverse effects are gastrointestinal, which are transient and less common with the long-acting drugs. GLP-1RAs are recommended as second-line therapy in combination with metformin, sulfonylureas, thiazolidinediones or basal insulin, providing a means of enhancing glucose control while offsetting the weight gain associated with insulin and some oral agents. GLP-1RAs represent a useful tool that the primary care physician can use to help patients with T2DM achieve their therapeutic goals.

Overview

Integrity signals

Registry

Crossref · 10.1080/00325481.2015.1090295

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 56 references

Research works printed but not linked: 12

  1. Centers for Disease Control and Prevention, 2014, National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014
  2. TRULICITY (dulaglutide) injection, for subcutaneous use, 2015, US prescribing information
  3. TANZEUM (albiglutide) for injection, for subcutaneous use, 2015, US prescribing information
  4. BYETTA (exenatide) injection, 2015, US prescribing information
  5. VICTOZA (liraglutide [rDNA origin] injection), 2015, US prescribing information
  6. BYDUREON (exenatide extended-release for injectable suspension), 2015, US prescribing information
  7. Jimenez-Solem E, 2010, Curr Opin Mol Ther, 12, 790
  8. Kapitza C, 2012, Diabetologia, 55, S341
  9. Abdul-Ghani MA, 2013, J Endocrinol Invest, 36, 168
  10. Rosenwasser RF, 2013, Diabetes Metab Syndr Obes, 6, 453
  11. Saxenda (liraglutide [rDNA origin] injection), 2015, US prescribing information
  12. Koro CE, 2013, Diabetes, 62, A415

Cited by

See all 128

Metadata

Authors
Shaefer, C. F., Kushner, P., & Aguilar, R.
Affiliations
  • Augusta University (US)
  • Diabetes Canada (CA)
Corresponding author
Shaefer, Charles F
Venue
Postgraduate Medicine
Published
2015-09-15
Volume
127
Issue
8
Pages
818-826
ISSN
  • 0032-5481 (ISSN-L)
  • 1941-9260
OpenAlex
W1863540633
Cited by
128
References
56
Citations by year
2026: 16 · 2025: 31 · 2024: 35 · 2023: 23 · 2022: 13 · 2021: 1 · 2020: 2 · 2018: 3 · 2017: 3 · 2016: 1
FWCI
0.35
Type
journal article
Language
en
Open access
closed
Locations
  • Postgraduate Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
GLP-1 receptor agonists, type 2 diabetes, exenatide, liraglutide, albiglutide, dulaglutide, mechanism of action, glycemic control, weight loss, hypoglycemia risk, gastrointestinal adverse effects, primary care management
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Blood Glucose, Energy Intake, Delayed-Action Preparations, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Gastric Emptying, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Metformin, Pancreas, Primary Health Care, Weight Loss, Glucagon-Like Peptide 1, Incretins, Medication Adherence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: User’s guide to mechanism of action and clinical use of GLP-1 receptor agonists. https://app.cochat.ai/papers/10.1080/00325481.2015.1090295
The paper
Shaefer, C. F., Kushner, P., & Aguilar, R. (2015). User’s guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgraduate Medicine. https://doi.org/10.1080/00325481.2015.1090295

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.